{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:01:33Z","timestamp":1785416493409,"version":"3.56.0"},"reference-count":45,"publisher":"IMR Press","issue":"7","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2023 Anhui Provincial Health Science and Technology Project","award":["AHWJ2023A30205"],"award-info":[{"award-number":["AHWJ2023A30205"]}]},{"name":"2024 Anhui Provincial Health Science and Technology Project","award":["2024BAd20017"],"award-info":[{"award-number":["2024BAd20017"]}]},{"name":"2023 Suzhou City Science and Technology Plan Project","award":["SZKJXM202428"],"award-info":[{"award-number":["SZKJXM202428"]}]},{"name":"2023 Suzhou City Health Science and Technology Project","award":["SZWJ2023a001"],"award-info":[{"award-number":["SZWJ2023a001"]}]},{"name":"2023 Anhui Medical University Scientific Research Project","award":["2023xkj075"],"award-info":[{"award-number":["2023xkj075"]}]},{"name":"2021 Suzhou City Science and Technology Plan Project","award":["SZSKJJZC030"],"award-info":[{"award-number":["SZSKJJZC030"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background:Methyltransferase-like 9 (METTL9) has been implicated in tumor progression, yet its clinical significance, functional roles, and immunoregulatory functions in lung adenocarcinoma (LUAD) remain unclear. This study aimed to integrate multi-omics datasets and experimental evidence to systematically evaluate the expression profile, prognostic value, molecular mechanisms, and tumor microenvironment (TME)-related functions of METTL9 in LUAD.Methods:Transcriptome and clinical data for LUAD and METTL9 protein expression were obtained from public databases. Survival analysis was performed using Kaplan\u2013Meier analysis and Cox proportional hazards models. METTL9-related differentially expressed genes (DEGs) were screened, followed by functional annotation and pathway enrichment analysis. A protein-protein interaction (PPI) network associated with METTL9 was constructed using STRING. METTL9 gene mutations and promoter methylation levels were analyzed via cBioPortal and UALCAN. Immune infiltration was evaluated through gene set variation analysis (GSVA) and the TIMER platform. The role of METTL9 depletion in regulating transforming growth factor-\u03b2 (TGF-\u03b2)\/Smad signaling, epithelial-mesenchymal transition (EMT), as well as the behavior of A549 and H1975 cells was investigated.Results:METTL9 was markedly elevated in LUAD, which was confirmed in external datasets and immunohistochemistry. Increased METTL9 expression showed a strong association with advanced TNM stage, unfavorable clinicopathological parameters, and poor survival outcomes in univariate analysis. Receiver operating characteristic (ROC) analysis indicated that METTL9 showed moderate diagnostic utility for LUAD, with an Area Under the Curve (AUC) of 0.704 (95% Confidence Interval [CI]: 0.650\u20130.758) in the The Cancer Genome Atlas (TCGA) dataset and 0.815 (95% CI: 0.758\u20130.872) in the GSE31210 dataset. Moreover, high METTL9 expression was significantly correlated with poor survival outcomes (Hazard Ratio [HR] = 1.349, 95% CI: 1.010\u20131.802, p = 0.043). METTL9 interacted with multiple oncogenic proteins in the PPI network and showed significant correlations with cuproptosis-related genes. Immune infiltration analysis further demonstrated that METTL9 expression showed significantly associated with immune cell infiltration and the tumor immune microenvironment in LUAD. METTL9 knockdown suppressed LUAD cell proliferation, migration, invasion, and EMT, while promoting apoptosis and reducing the expression of B-cell lymphoma 2 (Bcl-2), phosphorylated Smad2 (p-smad2), and phosphorylated Smad3 (p-smad3).Conclusion:METTL9 is upregulated in LUAD and correlates with an unfavorable prognosis. Our results indicate that METTL9 may contribute to LUAD progression and EMT, potentially in relation to the TGF-\u03b2\/Smad signaling pathway.<\/jats:p>","DOI":"10.31083\/fbl49673","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:17:49Z","timestamp":1785413869000},"source":"Crossref","is-referenced-by-count":0,"title":["Integrative Bioinformatics and Experimental Validation Reveal that METTL9 Drives Lung Adenocarcinoma Progression via TGF-\u03b2\/Smad-Mediated EMT Activation"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8594-4005","authenticated-orcid":true,"given":"Chen","family":"Gong","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmaceutical Sciences, Anhui Medical University, 230032 Hefei, Anhui, China"},{"name":"Clinical Research Center, Suzhou Hospital of Anhui Medical University, 234000 Suzhou, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5674-7739","authenticated-orcid":true,"given":"Yuyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Suzhou Hospital of Anhui Medical University, 234000 Suzhou, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9815-4906","authenticated-orcid":true,"given":"Yuchen","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiac Surgery, Suzhou Hospital of Anhui Medical University, 234000 Suzhou, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9589-212X","authenticated-orcid":true,"given":"Yuling","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Suzhou Hospital of Anhui Medical University, 234000 Suzhou, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-7426","authenticated-orcid":true,"given":"La","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmaceutical Sciences, Anhui Medical University, 230032 Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-2107","authenticated-orcid":true,"given":"Haoyuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiac Surgery, Suzhou Hospital of Anhui Medical University, 234000 Suzhou, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiac Surgery, Zhoushan Hospital of Wenzhou Medical University, 316000 Zhoushan, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1445-448X","authenticated-orcid":true,"given":"Bin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmaceutical Sciences, Anhui Medical University, 230032 Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3089-4386","authenticated-orcid":true,"given":"Xueqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiac Surgery, Suzhou Hospital of Anhui Medical University, 234000 Suzhou, Anhui, China"},{"name":"Department of Thoracic and Cardiac Surgery, Zhoushan Hospital of Wenzhou Medical University, 316000 Zhoushan, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Seguin L, Durandy M, Feral CC. Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine. Cancers. 2022; 14: 1759.","DOI":"10.3390\/cancers14071759"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer. 2023; 22: 40.","DOI":"10.1186\/s12943-023-01740-y"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Li J, Wang Y, Liu Y, Liu Q, Shen H, Ren X, et al. Survival analysis and clinicopathological features of patients with stage IA lung adenocarcinoma. Heliyon. 2024; 10: e23205.","DOI":"10.1016\/j.heliyon.2023.e23205"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wang Q, Xue F, Assaraf YG, Lin Y. Harnessing Natural Products to Surmount Drug Resistance in Gastric Cancer: Mechanisms and Therapeutic Perspectives. International Journal of Biological Sciences. 2025; 21: 4604\u20134628.","DOI":"10.7150\/ijbs.113709"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Qi YN, Liu Z, Hong LL, Li P, Ling ZQ. Methyltransferase-like proteins in cancer biology and potential therapeutic targeting. Journal of Hematology & Oncology. 2023; 16: 89.","DOI":"10.1186\/s13045-023-01477-7"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Wu S, Guo D, Hu X, Yang M. The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications. Biomarker Research. 2025; 13: 141.","DOI":"10.1186\/s40364-025-00858-z"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Sun Y, Shen W, Hu S, Lyu Q, Wang Q, Wei T, et al. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. Journal of Experimental & Clinical Cancer Research : CR. 2023; 42: 65.","DOI":"10.1186\/s13046-023-02638-9"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Sun Y, Gong W, Zhang S. METTL3 promotes colorectal cancer progression through activating JAK1\/STAT3 signaling pathway. Cell Death & Disease. 2023; 14: 765.","DOI":"10.1038\/s41419-023-06287-w"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Kang N, Zhao Z, Wang Z, Ning J, Wang H, Zhang W, et al. METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8. International Journal of Biological Sciences. 2024; 20: 3426\u20133441.","DOI":"10.7150\/ijbs.84797"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Zhang P, Xiang H, Peng Q, Ma L, Weng C, Liu G, et al. METTL14 attenuates cancer stemness by suppressing ATF5\/WDR74\/\u03b2-catenin axis in gastric cancer. Cancer Science. 2025; 116: 112\u2013127.","DOI":"10.1111\/cas.16381"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Hou Y, Zhang X, Yao H, Hou L, Zhang Q, Tao E, et al. METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53-wild-type cells. EMBO Reports. 2023; 24: e56325.","DOI":"10.15252\/embr.202256325"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Codino A, Spagnoletti L, Olobardi C, Cuomo A, Santos-Rosa H, Palomba M, et al. METTL9 sustains vertebrate neural development primarily via non-catalytic functions. Nature Communications. 2025; 16: 7051.","DOI":"10.1038\/s41467-025-62414-5"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Jin J, Li Q, Zhang Y, Ji P, Wang X, Zhang Y, et al. METTL9 mediated N1-Histidine methylation of SLC39A7 confers ferroptosis resistance and inhibits adipogenic differentiation in mesenchymal stem cells. Molecular Medicine (Cambridge, Mass.). 2025; 31: 206.","DOI":"10.1186\/s10020-025-01271-w"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Li M, Zhi Z, Jiang X, Duan GC, Zhu WN, Pang Z, et al. METTL9 derived circular RNA circ-METTL9 sponges miR-551b-5p to accelerate colorectal cancer progression by upregulating CDK6. Carcinogenesis. 2023; 44: 463\u2013475.","DOI":"10.1093\/carcin\/bgad031"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Bi F, Qiu Y, Wu Z, Liu S, Zuo D, Huang Z, et al. METTL9-SLC7A11 axis promotes hepatocellular carcinoma progression through ferroptosis inhibition. Cell Death Discovery. 2023; 9: 428.","DOI":"10.1038\/s41420-023-01723-4"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens. 2007; 69: 1\u20139.","DOI":"10.1111\/j.1399-0039.2006.00739.x"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Srinivasan D, Balakrishnan R, Chauhan A, Kumar J, Girija DM, Shrestha R, et al. Epithelial-Mesenchymal Transition in Cancer: Insights Into Therapeutic Targets and Clinical Implications. MedComm. 2025; 6: e70333.","DOI":"10.1002\/mco2.70333"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W, et al. METTL3\/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer. Molecular Cancer. 2022; 21: 60.","DOI":"10.1186\/s12943-021-01447-y"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Ouyang P, Li K, Xu W, Chen C, Shi Y, Tian Y, et al. METTL3 recruiting M2-type immunosuppressed macrophages by targeting m6A-SNAIL-CXCL2 axis to promote colorectal cancer pulmonary metastasis. Journal of Experimental & Clinical Cancer Research : CR. 2024; 43: 111.","DOI":"10.1186\/s13046-024-03035-6"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Miyake K, Costa Cruz PH, Nagatomo I, Kato Y, Motooka D, Satoh S, et al. A cancer-associated METTL14 mutation induces aberrant m6A modification, affecting tumor growth. Cell Reports. 2023; 42: 112688.","DOI":"10.1016\/j.celrep.2023.112688"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Li L, Zeng J, He S, Yang Y, Wang C. METTL14 decreases FTH1 mRNA stability via m6A methylation to promote sorafenib-induced ferroptosis of cervical cancer. Cancer Biology & Therapy. 2024; 25: 2349429.","DOI":"10.1080\/15384047.2024.2349429"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Zehentner S, Reiner AT, Grimm C, Somoza V. The Role of Bitter Taste Receptors in Cancer: A Systematic Review. Cancers. 2021; 13: 5891.","DOI":"10.3390\/cancers13235891"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Zheng M, Zhou J, Wang Y. Primary cilia in cancer: structures, functions, mechanisms, and therapeutic implications. Cancer Biology & Medicine. 2025; 22: 1455\u20131472.","DOI":"10.20892\/j.issn.2095-3941.2025.0340"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Li W, Xie R, Chen H, Lin J, Zhong M, Zhang J, et al. METTL1-mediated m7G tRNA modification drives papillary thyroid cancer progression and metastasis by regulating the codon-specific translation of TNF-\u03b1. Cell Death & Disease. 2025; 16: 378.","DOI":"10.1038\/s41419-025-07716-8"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Wei W, Zhang ZY, Shi B, Cai Y, Zhang HS, Sun CL, et al. METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression. Journal of Experimental & Clinical Cancer Research : CR. 2023; 42: 151.","DOI":"10.1186\/s13046-023-02732-y"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Davydova E, Shimazu T, Schuhmacher MK, Jakobsson ME, Willemen HLDM, Liu T, et al. The methyltransferase METTL9 mediates pervasive 1-methylhistidine modification in mammalian proteomes. Nature Communications. 2021; 12: 891.","DOI":"10.1038\/s41467-020-20670-7"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Markowitz J, Carson WE 3rd. Review of S100A9 biology and its role in cancer. Biochimica et Biophysica Acta. 2013; 1835: 100\u2013109.","DOI":"10.1016\/j.bbcan.2012.10.003"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Rai NK, Venugopal H, Rajesh R, Ancha P, Venkatesh S. Mitochondrial complex-1 as a therapeutic target for cardiac diseases. Molecular and Cellular Biochemistry. 2025; 480: 869\u2013890.","DOI":"10.1007\/s11010-024-05074-1"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Fan W, Xing Y, Yan S, Liu W, Ning J, Tian F, et al. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-\u03b2\/Smad signaling pathway in lung adenocarcinoma. Cancer Cell International. 2024; 24: 208.","DOI":"10.1186\/s12935-024-03382-6"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Wang S, Li Y, Jin K, Suda K, Li R, Zhang H, et al. PSME3 promotes lung adenocarcinoma development by regulating the TGF-\u03b2\/SMAD signaling pathway. Translational Lung Cancer Research. 2024; 13: 1331\u20131345.","DOI":"10.21037\/tlcr-24-340"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Miao T, Zhang Y, Tian F, Xu X, Wei Q, Jiang X, et al. Down-regulation of MFNG promotes the metastatic potential of lung adenocarcinoma by regulating TGF-\u03b2\/Smad signaling. iscience. 2025; 28: 113647.","DOI":"10.1016\/j.isci.2025.113647"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RWC, et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell. 2017; 171: 1284\u20131300.e21.","DOI":"10.1016\/j.cell.2017.10.022"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD. Epigenetic therapy in immune-oncology. Nature Reviews. Cancer. 2019; 19: 151\u2013161.","DOI":"10.1038\/s41568-019-0109-9"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhang L, Zhou F. Cuproptosis: a new form of programmed cell death. Cellular & Molecular Immunology. 2022; 19: 867\u2013868.","DOI":"10.1038\/s41423-022-00866-1"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Li Y, Du Y, Zhou Y, Chen Q, Luo Z, Ren Y, et al. Iron and copper: critical executioners of ferroptosis, cuproptosis and other forms of cell death. Cell Communication and Signaling : CCS. 2023; 21: 327.","DOI":"10.1186\/s12964-023-01267-1"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"An J, Song W, Wang Q, Tan B, Fei X, Wang R, et al. Role of the SPI1\/CDKN2A\/p53 signaling pathway in cuproptosis of lung adenocarcinoma cells. Oncology Letters. 2025; 30: 353.","DOI":"10.3892\/ol.2025.15099"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Yang W, Wang Y, Huang Y, Yu J, Wang T, Li C, et al. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2023; 159: 114301.","DOI":"10.1016\/j.biopha.2023.114301"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Hu Y, Liu H, Tan X, Wu X. Knocking Down Ferredoxin 1 Inhibits the Progression of Colorectal Cancer and Regulates Cuproptosis via Mediating the Hippo Signaling Pathway. Molecular Carcinogenesis. 2025; 64: 911\u2013922.","DOI":"10.1002\/mc.23897"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Huang Y, Shan G, Yi Y, Liang J, Hu Z, Bi G, et al. FSCN1 induced PTPRF-dependent tumor microenvironment inflammatory reprogramming promotes lung adenocarcinoma progression via regulating macrophagic glycolysis. Cellular Oncology (Dordrecht, Netherlands). 2022; 45: 1383\u20131399.","DOI":"10.1007\/s13402-022-00726-0"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Wang L, Li Q, Sun Y, Wang S, Fu X, Wang X, et al. Tumor-derived immunoglobulin-like transcript 3 inhibition reshapes the immunosuppressive tumor microenvironment and potentiates programmed cell death ligand 1 blockade immunotherapy in lung adenocarcinoma. Translational Oncology. 2025; 56: 102381.","DOI":"10.1016\/j.tranon.2025.102381"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Li Y, Liu Y, Wang K, Xue D, Huang Y, Tan Z, et al. STK24 Promotes Progression of LUAD and Modulates the Immune Microenvironment. Mediators of Inflammation. 2023; 2023: 8646088.","DOI":"10.1155\/2023\/8646088"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Sun C, Wang J, Li H, Liu L, Lin Y, Zhang L, et al. METTL14 regulates CD8+T-cell activation and immune responses to anti-PD-1 therapy in lung cancer. World Journal of Surgical Oncology. 2024; 22: 128.","DOI":"10.1186\/s12957-024-03402-9"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Wu X, Zhu Z, Zhang J, Tian M, Zhao P. Progress in understanding the regulatory mechanisms of immune checkpoint proteins PD-1 and PD-L1 expression. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2025; 27: 3261\u20133271.","DOI":"10.1007\/s12094-024-03835-4"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Mondal K, Posa MK, Shenoy RP, Roychoudhury S. KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways. Cells. 2024; 13: 1221.","DOI":"10.3390\/cells13141221"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Ghosh S, Bhuniya T, Dey A, Koley M, Roy P, Bera A, et al. An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health. Applied Biochemistry and Biotechnology. 2024; 196: 4661\u20134678.","DOI":"10.1007\/s12010-023-04748-8"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/7\/10.31083\/FBL49673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:18:04Z","timestamp":1785413884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/7\/10.31083\/FBL49673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02171-4"],"URL":"https:\/\/doi.org\/10.31083\/fbl49673","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"49673"}}